Novo Nordisk
NVO
501 hedge funds and large institutions have $8.53B invested in Novo Nordisk in 2014 Q4 according to their latest regulatory filings, with 65 funds opening new positions, 185 increasing their positions, 166 reducing their positions, and 27 closing their positions.
141% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 27
11% more repeat investments, than reductions
Existing positions increased: 185 | Existing positions reduced: 166
7% more funds holding
Funds holding: 470 → 501 (+31)
0.83% more ownership
Funds ownership: 18.24% → 19.06% (+0.83%)
3% less call options, than puts
Call options by funds: $4.16M | Put options by funds: $4.29M
7% less capital invested
Capital invested by funds: $9.17B → $8.53B (-$644M)
28% less funds holding in top 10
Funds holding in top 10: 25 → 18 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$86M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$85.4M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$36.6M |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$34.6M |
| 5 |
Millennium Management
New York
|
+$25.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$182M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$49.9M |
| 3 |
Lazard Asset Management
New York
|
-$36.1M |
| 4 |
Renaissance Technologies
New York
|
-$22M |
| 5 |
Bank of New York Mellon
New York
|
-$15.5M |
NVO Hedge Fund Activity: Q4 2014 in Review
501 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q4 2014, worth a combined $8.53B — down 7% from $9.17B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new NVO positions and 27 closed out — a net gain of 38 holders — while 185 added to existing stakes and 166 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $86M. The largest seller was Jennison Associates, cutting an estimated $182M.
- 501 institutional investors held Novo Nordisk (NVO) as of Q4 2014, up from 470 in Q3 2014.
- Funds reported $8.53B of Novo Nordisk stock for Q4 2014, down 7% quarter-over-quarter.
- 65 funds opened new Novo Nordisk positions in Q4 2014 and 27 closed out, a net change of +38 holders.
- The largest Novo Nordisk buyer in Q4 2014 was Arrowstreet Capital, an estimated $86M added.
- The largest Novo Nordisk seller in Q4 2014 was Jennison Associates, an estimated $182M sold.
Based on aggregated 13F filings for Q4 2014.